Scalper1 News
Myriad Genetics (MYGN) stock tumbled in early trading on the stock market today after a court late Monday denied it a preliminary injunction against a rival. Myriad has been trying to stop the entry of rival versions of its BRACAnalysis test for genetic susceptibility to breast cancer, ever since the Supreme Court invalidated some of its patents last year on the basis that genes are unpatentable. This particular case involved privately held Ambry Scalper1 News
Scalper1 News